GlassScriptPhysician profile
Igor V Aksenov
NPI 1699854224
$4,226.81
in general payments reported to CMS, 2019-2025
40 companies · $695 in 2025
The $695 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $78.43 · 2021: $341 · 2022: $680 · 2023: $1,012 · 2024: $1,108 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,527 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,526.92 |
| Education | $288.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $913.86 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Regeneron Healthcare Solutions, INC. | $325.70 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $300.53 | 2022-2025 | Fasenra, Airsupra |
| Genzyme Corporation | $294.28 | 2022-2025 | |
| Axsome Therapeutics, INC. | $280.05 | 2023-2024 | Sunosi |
| Pulmonx Corporation | $179.60 | 2023-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Amgen INC. | $174.99 | 2022-2025 | Tezspire |
| Insmed, INC. | $168.68 | 2021-2025 | Arikayce |
| Philips North America LLC | $146.72 | 2019-2023 | |
| Abiomed | $114.93 | 2022 | |
| United Therapeutics Corporation | $110.95 | 2021-2024 | Tyvaso |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Merck Sharp & Dohme LLC | $86.96 | 2019-2025 | Belsomra, Zerbaxa |
| Jazz Pharmaceuticals INC. | $78.08 | 2023-2024 | Xywav |
| Grifols USA, LLC | $72.17 | 2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Aksenov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.